The firm said the assay is an enhanced version of a test it made available this summer that measures the amount of neutralizing antibodies to SARS-CoV-2.
The firm's CFO Jochen Schmitz said the upside from COVID-19 testing only partly compensated for a steep decline in reagent volumes used in routine care testing.
The company said its rapid antigen test provides results in 15 minutes and is easy to administer for healthcare professionals using a nasopharyngeal swab.
The company's recent license agreement with Abbott is part of its plan to move its Simoa technology into the clinic via partners in LDT and IVD development.
Semi-quantitative SARS-CoV-2 serology tests enable users to measure levels of neutralizing antibodies, but tests need to be more comparable across manufacturers, Siemens said.
The company is developing technology to analyze capillary blood samples from a finger prick using one-tenth the volume typically collected by traditional venipuncture.
Questions around performance and a lack of clear clinical utility have hampered uptake, though improved standardization and vaccine launches could boost usage.
